AMG National Trust Bank Invests $6.83 Million in Edwards Lifesciences Corporation $EW

Key Points

• AMG National Trust Bank acquired 75,472 shares of Edwards Lifesciences in the second quarter, valued at approximately $6.83 million. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus the $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $100.27, compared with the stock’s recent price of $91.51.

AMG National Trust Bank acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 75,472 shares of the medical research company's stock, valued at approximately $6,827,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $1,274,082,000. Norges Bank bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after buying an additional 4,108,270 shares during the period. Viking Global Investors LP acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $238,688,000. Finally, Marshall Wace LLP increased its position in Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company's stock valued at $505,160,000 after buying an additional 2,359,128 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company's stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,570 shares of company stock worth $2,219,390 in the last three months. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $91.51 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm has a 50-day moving average of $88.73 and a 200-day moving average of $84.38. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a market cap of $52.69 billion, a P/E ratio of 52.59, a P/E/G ratio of 2.30 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. Evercore reaffirmed an "outperform" rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Mizuho boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a report on Wednesday, July 15th. Piper Sandler reaffirmed an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Finally, Barclays reissued an "overweight" rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source